Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs The Travelers Companies Inc. Common Stock (TRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs The Travelers Companies Inc. Common Stock — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while The Travelers Companies Inc. Common Stock trades at $382.95 (market cap $77.86B). The key difference: The Travelers Companies Inc. Common Stock is far larger — about 10.4× Spyre Therapeutics Inc. Common Stock's market cap, and The Travelers Companies Inc. Common Stock pays a 1.34% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and The Travelers Companies Inc. Common Stock for 6 Days on average.
| SYRE | TRV | |
|---|---|---|
Market Cap | $7.52B | $77.86B |
Volume | 1,441,031 | 986,776 |
Sector | Health | Financials |
52-Week High | $108.92 | $397.22 |
52-Week Low | $22.18 | $261.57 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.52B | $86.44B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TRV trades at $373.28, up 0.43% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.03 and ROE of 26.32%, while consistently beating earnings estimates in recent quarters. Recent news highlights Travelers' earnings momentum ahead of Q3 results.
The outlook remains positive given valuation attractiveness and earnings beat history, though risks include competitive pressures and potential earnings volatility. Analyst consensus is mixed with 25% buy ratings but a $353.80 price target below current levels, suggesting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About The Travelers Companies Inc. Common Stock
The Travelers Companies provides property and casualty insurance for individuals, businesses, and organizations. Its products include auto, home, and commercial coverage.
Read more on TRV →
